Related Experiment Video

Updated: Jun 21, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

Jingchun Gao1, Zhong Zheng, Bhupendra Rawal

  • 1Department of Experimental Therapeutics and Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA.

Cancer Biology & Therapy
|July 28, 2009
PubMed

Insights

Minibrain-related kinase (Mirk) is overexpressed in non-small cell lung cancer (NSCLC) and promotes cancer cell survival. Inhibiting Mirk induces apoptosis and may offer a new therapeutic strategy for lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Minibrain-related kinase (Mirk/Dyrk1B) is a dual-specificity kinase implicated in various solid tumors.
  • Mirk's role in lung cancer, particularly non-small cell lung cancer (NSCLC), is not well-established.
  • Previous studies show Mirk upregulation in colon cancer, pancreatic ductal adenocarcinoma, and rhabdomyosarcomas, mediating cell survival.

Purpose of the Study:

  • To investigate the expression and function of Mirk in non-small cell lung cancer (NSCLC).
  • To determine if Mirk acts as a survival factor in NSCLC cells.
  • To evaluate Mirk as a potential therapeutic target for lung cancer.

Main Methods:

  • Western blotting and immunoprecipitation to assess Mirk protein expression and phosphorylation in NSCLC cell lines.
  • Small interfering RNA (siRNA) to knockdown Mirk expression and analyze its effects on apoptosis, cell signaling (STAT3, Bak), and colony formation.
  • Orthotopic mouse model to evaluate Mirk's role in tumor growth in vivo.
  • Automated quantitative determination of Mirk protein in early-stage lung cancer patient tumor specimens.

Main Results:

  • Mirk protein was overexpressed in 13 of 19 NSCLC cell lines and in nearly 90% of early-stage lung cancer patient tumor specimens (cytoplasmic and nuclear localization).
  • Mirk knockdown induced apoptosis, upregulated Bak, and downregulated STAT3 tyrosine phosphorylation in NSCLC cells.
  • Mirk knockdown reduced colony formation in vitro, delayed tumor growth in an orthotopic mouse model, and sensitized cells to cisplatin-induced apoptosis.

Conclusions:

  • Mirk is significantly overexpressed in lung cancer and functions as a survival factor for cancer cells.
  • Mirk plays a critical role in NSCLC progression and chemoresistance.
  • Mirk represents a promising novel therapeutic target for the treatment of lung cancer.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...